The Efficacy and Safety of the Combined Therapy of Sodium-Glucose Co-Transporter-2 Inhibitors and Angiotensin Receptor-Neprilysin Inhibitor in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-Analysis of the EMPEROR-Reduced and DAPA-HF Sub-Analysis

BACKGROUND: Both sodium-glucose co-transporter-2 (SGLT-2) inhibitors and angiotensin receptor-neprilysin inhibitor (ARNI) were recommended to treat heart failure with reduced ejection fraction (HFrEF). However, no trial was conducted to assess the efficacy and safety of the combined therapy of SGLT-...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Yanxia, Zhang, Huanrui, Zhao, Shijie, Chen, Ling, Li, Jinyang, Wang, Xiaoou, Tian, Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157547/
https://www.ncbi.nlm.nih.gov/pubmed/35665248
http://dx.doi.org/10.3389/fcvm.2022.882089

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157547/
https://www.ncbi.nlm.nih.gov/pubmed/35665248
http://dx.doi.org/10.3389/fcvm.2022.882089

Ejemplares similares